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Abstract  
 
Precision	 medicine	 requires	 a	 robust,	 standardised	 and	 reproducible	 assessment	 of	
predictive	 and	 prognostic	 biomarkers,	 to	 replace	 current	 laborious	 and	 inaccurate	
manual	 scoring	 approaches.	 Output	 from	 common	 tissue‐based	 biomarker	 studies	
involving	 immunohistochemistry	applied	 to	 tissue	microarrays	(TMA)	 is	 limited	by	 the	
lack	of	an	efficient	and	reproducible	scoring	methodology.	In	this	study,	we	examine	the	
functionality	and	reproducibility	of	biomarker	scoring	using	the	new,	open	source,	digital	
image	analysis	software,	QuPath.	
	
Three	different	reviewers,	with	varying	experience	of	digital	pathology	and	image	analysis,	
applied	 an	 agreed	 QuPath	 scoring	 methodology	 to	 CD3	 and	 p53	 immunohistochemically	
stained	TMAs	 from	a	 colon	 cancer	 cohort	 (n=661).	Manual	 assessment	was	 conducted	by	
one	 reviewer	 for	 CD3.	 Survival	 analyses	 were	 conducted	 and	 intra‐	 and	 inter‐observer	
reproducibility	assessed.	
	
Median	raw	scores	for	CD3	and	p53	differed	significantly	between	reviewers	but	this	had	
little	impact	on	subsequent	analyses.	Lower	CD3	scores	were	detected	in	cases	who	died	
from	colorectal	cancer,	compared	to	control	cases,	and	this	finding	was	significant	for	all	
three	 reviewers	 (p‐value	 range	0.002‐0.02).	 	Higher	median	p53	 scores	were	 generated	
amongst	cases	who	died	from	colorectal	cancer	compared	with	controls,	but	this	 finding	
was	 borderline	 or	 non‐significant	 for	 all	 three	 reviewers	 (p‐value	 range	 0.04‐0.12).	 The	
ability	 to	 dichomotise	 cases	 into	 high	 versus	 low	 expression	 of	 CD3	 and	 p53	 showed	
excellent	agreement	between	all	three	reviewers	(Kappa	score	range	0.82‐0.93).	All	three	
reviewers	produced	dichotomised	expression	scores	that	resulted	 in	very	similar	hazard	
ratios	 and	 95%	 confidence	 intervals	 for	 colorectal	 cancer‐specific	 survival	 for	 each	
biomarker.	 Results	 from	manual	 and	QuPath	methods	 of	 CD3	 scoring	were	 comparable,	
but	QuPath	scoring	revealed	stronger	prognostic	stratification	compared	to	manual	scores,	
suggesting	greater	scoring	accuracy	compared	to	the	manual	method.		
	
Scoring	of	 immunohistochemically	 stained	 tumour	TMAs	using	QuPath	 is	 functional	 and	
reproducible,	 even	 amongst	 users	 of	 limited	 experience	 in	 digital	 pathology	 and	 image	
analysis,	 and	 more	 accurate	 than	 manual	 scoring.	 Digital	 image	 analysis,	 such	 as	 that	
performed	here,	has	the	potential	to	alleviate	a	major	bottleneck	in	biomarker	discovery	
and	validation	studies.	
   
Introduction 
 
Tissue‐based	 biomarker	 studies	 represent	 a	 cornerstone	 of	 current	 cancer	 research	
strategies.	 Many	 such	 studies	 involve	 immunohistochemistry	 (IHC)	 applied	 to	 tissue	
microarrays	 (TMA),	 to	 allow	high	 throughput	 analysis	of	multiple	 tumour	 samples.	 [1]	
Output	 from	 such	 research	 is	 limited	 by	 the	 lack	 of	 an	 accurate,	 robust	 and	 efficient	
automated	method	of	scoring	IHC‐stained	markers	on	TMAs,	to	replace	current	laborious	
and	expensive	manual	approaches,	usually	conducted	by	pathologists.	This	represents	a	
major	bottleneck	to	biomarker	discovery	and	validation	studies.	
	
Developments	 in	 digital	 image	 analysis	 afford	 the	 potential	 to	 overcome	 some	 of	 the	
major	drawbacks	associated	with	manual	 scoring.	 [2]	Until	 recently,	 the	 field	of	digital	
pathology	 lacked	an	open	and	accessible	bioimage	analysis	software	platform	designed	
to	meet	 the	unique	 challenges	 involved	 in	 analysing	ultra‐large	2D	whole	 slide	 images	
(up	to	40GB	uncompressed	data	per	slide),	the	mainstay	of	digital	pathology.	
	
QuPath	 (https://qupath.github.io)	 is	 new,	 comprehensive	 digital	 pathology	 image	
analysis	 software,	 developed	 at	 Queen’s	 University	 Belfast	 to	 address	 these	 needs,	
offering	an	open‐source	bioimage	analysis	platform	that	improves	the	speed,	objectivity	
and	reproducibility	of	digital	pathology	analysis	and	 is	capable	of	handling	whole	slide	
images.	 [3]	 Its	 functionality	 also	 permits	 training	 and	 subsequent	 classification	 of	
tumour	and	non‐tumour	cells	using	automated	digital	algorithms,	with	instant	mark‐up	
available	for	continuous	review	of	the	training	process,	in	a	manner	amenable	to	visual	
inspection	and	quality	 control	by	a	pathologist.	Evaluation	of	 IHC‐stained	TMAs	 is	 just	
one	 of	 many	 potential	 applications	 of	 QuPath,	 but	 one	 we	 see	 as	 most	 valuable	 to	
biomarker	 discovery	 research.	 As	 with	 any	 new	 methodology,	 validation	 by	
demonstration	of	inter‐observer	reproducibility	and	by	intra‐observer	comparison	with	
the	current	gold	standard,	manual	assessment	in	this	case,	 is	an	essential	step	towards	
acceptance	into	common	usage.		
	
Recent	 studies	 have	 evaluated	 the	 application	 of	QuPath	to	 the	 scoring	 of	 a	 variety	 of	
different	biomarkers	 in	breast	 and	 colon	 cancer	 tissue	 cohorts,	mainly	 in	TMA	 format.	
[3‐6]	 In	 this	 study,	 we	 aim	 to	 demonstrate	 the	 functionality	 and	 reproducibility	 of	
biomarker	 scoring	 using	 QuPath	 image	 analysis	 involving	 users	 from	 different	
backgrounds	 (pathology,	 computer	 science,	 biochemistry)	 and	 with	 varying	 levels	 of	
experience	of	digital	image	analysis.	Two	well‐established	and	biologically	distinct	tissue	
biomarkers,	 CD3	and	p53,	were	 evaluated	 in	 IHC‐stained	TMAs	 from	a	 large	 cohort	 of	
colon	 cancers	 by	 the	 three	 study	 reviewers	 using	 QuPath,	 and	 inter‐observer	
reproducibility	 of	 raw	 scores	 and	 downstream	 survival	 analyses	 assessed.	 Manual	
scoring	 was	 conducted	 by	 one	 participant	 and	 manual	 versus	 QuPath	 method	 intra‐
observer	 reproducibility	 assessed.	 Comparison	 of	 prognostic	 stratification	 applying	
manual	 and	 QuPath	 scores	 for	 the	 established	 prognostic	 marker	 CD3,	 provides	 an	
external	benchmark	for	assessment,	related	to	patient	outcomes.	
	 	
Materials	and	Methods	
	
Patient	Cohort	
	
The	study	utilised	an	established	cohort	of	661	stage	II	and	III	colon	cancer	cases,	
whose	surgical	 resection	specimens	were	 retrieved	as	part	of	 the	creation	of	 the	
Northern	 Ireland	 Colon	 Cancer	 Tissue	 and	 Data	 resource.	 The	 methods	 for	 the	
creation	of	this	cohort	have	been	described	elsewhere.[5,	6]In	brief,	this	resource	
was	 created	 using	 a	 population‐based	 study	 design	whereby	 the	 cases	 retrieved	
were	 representative	 of	 all	 patients	 with	 stage	 II	 or	 III	 colon	 cancer	 who	 were	
diagnosed	 and	 underwent	 surgical	 resection	 between	 2004	 and	 2008.	 The	 661	
study	cases	represent	46%	of	all	 stage	 II	and	 III	 colon	cancer	cases	diagnosed	 in	
Northern	Ireland	during	this	time	period.		By	the	end	of	2013,	212	individuals	had	
died	from	a	colorectal	cancer‐specific	cause,	with	449	individuals	either	still	alive	
or	having	died	from	another	cause	during	this	timeframe	(hereafter	referred	to	as	
controls).		
	
	
Tissue	Microarray	Creation	
	
Representative	tumour	blocks	were	selected	following	review	of	all	original	glass	
slides	 from	 the	 surgical	 resection	 specimens	 and	 recut	 haematoxylin	 and	 eosin‐
stained	 sections	 annotated	 for	 TMA	 construction.	 Three	 1mm	 cores	 from	 the	
centre	 region	 of	 the	 tumour	 in	 each	 block	 were	 targeted,	 providing	 triplicate	
sampling	 of	 all	 661	 tumours,	 totalling	 n=1983	 tumour	 cores	 for	 scoring,	
represented	in	a	total	of	21	TMA	blocks.	
	
	
Immunohistochemistry	
	
4μm	sections	from	each	TMA	block	were	immunohistochemically	stained	for	CD3	
and	 p53.	 p53	 IHC	was	 performed	 on	 a	 Leica	 BondMax	 using	 the	 DO‐7	 antibody	
clone	 to	p53	(Dako	UK	Ltd,	Ely,	UK:	ER1	30mins	polymer	kit	detection)	and	CD3	
IHC	 was	 performed	 on	 a	 Ventana	 BenchMark	 using	 the	 antibody	 clone	
2GV6		(Ventana;	CC1	32minutes,	Optiview	detection),		as	previously	described.[6]	
	
These	biomarkers	were	chosen	as	both	are	well	characterised	and	antibodies	are	
in	routine	clinical	use	in	most	pathology	laboratories.	CD3	is	well	established	as	a	
prognostic	marker	in	colorectal	cancer,	high	CD3‐positive	T‐cell	tumour	infiltrates	
being	 associated	 with	 more	 favourable	 clinical	 outcomes.	 [7,	 8]	 The	 prognostic	
value	of	p53	expression	in	colorectal	cancer	is	less	well	established.		[9,	10]	More	
importantly,	 for	 the	 purposes	 of	 this	 study	 in	 assessing	QuPath	 versatility,	 these	
biomarkers	 demonstrate	 markedly	 different	 immunohistochemical	 staining	
patterns.	CD3	exclusively	 stains	T‐lymphocytes,	with	uniform	 intensity,	 and	with	
no	staining	of	 tumour	cells	or	other	non‐lymphoid	 tissue.	p53	stains	 tumour	and	
non‐tumour	cell	populations	(in	particular	reactive	lymphoid	cells)	and	staining	is	
of	 variable	 intensity	 ranging	 from	 negative	 to	 strongly	 positive.	 These	 different	
staining	 patterns	 and	 cell	 populations	 require	 different	 approaches	 to	 scoring,	
whether	adopting	manual	or	digital	image	analysis	approaches.	
	
	
Image	Analysis	
	
Stained	 TMA	 sections	were	 scanned	 using	 the	 Aperio	 ScanScope	 CS	whole	 slide	
scanner	 at	 x40	 magnification.	 Full	 details	 of	 QuPath	 including	 source	 code,	
documentation,	links	to	the	software	download	and	illustrative	video	supplements	
are	 available	 at	 https://qupath.github.io.	 The	 scanned	 images	 were	 dearrayed	
within	 QuPath	 and	 all	 cores	 examined	 during	 the	 scoring	 process	 to	 manually	
exclude	those	with	either	no	tumour	represented	or	with	artefacts	(tissue	folding,	
for	example)	precluding	assessment.		
	
Many	 different	 scoring	 methods	 are	 possible	 within	 QuPath	 and	 careful	
consideration	 is	 required	 to	 select	 the	 scoring	 method	 most	 appropriate	 to	 the	
biomarker	and	tissue	in	question.	Different	approaches	were	selected	for	CD3	and	
p53	 (Figure	 1).	 The	 single	 target	 cell	 population	 and	 uniform	 intensity	 staining	
pattern	 of	 CD3	 lends	 itself	 to	 assessment	 by	 a	 simple	 density	 method	 within	
QuPath	(Figure	1A).	This	involved	two	steps:	firstly,	the	total	tissue	area	(tumour	
and	 non‐tumour)	 in	 each	 core	 was	 detected	 using	 the	 Simple	 tissue	 detection	
command;	 secondly,	 numbers	 of	 cells	 staining	 positively	 for	 CD3	 were	 counted	
using	 the	Fast	cell	counts	 command.	From	these	data,	CD3	density	was	expressed	
as	 numbers	 of	 CD3‐positive	 cells	 per	mm2	 of	 tissue.	 A	 corresponding	 script	was	
then	 generated	 to	 run	 on	 all	 imported	 TMA	 images,	 thereby	 automating	 the	
detection	and	export	steps	across	slides.	
	
The	more	 complex	 staining	pattern	of	p53	 required	a	different	approach	 (Figure	
1B).	 Firstly,	 as	 staining	 is	 evident	 in	 tumour	 and	 non‐tumour	 cell	 populations,	 a	
classification	 step	 was	 required,	 using	 training	 and	 automated	 algorithms	 in	
QuPath	 to	 distinguish	 the	 tumour	 epithelial	 cell	 population	 of	 interest	 from	
background	 inflammatory	and	stromal	 cell	populations.	This	entailed	application	
of	 the	Cell	detection	 command	to	 identify	all	cells	 in	all	cores	based	upon	nuclear	
staining,	 then,	 using	 selected	measurements	 of	 intensity	 and	morphology	 for	 all	
cells,	 applying	a	 two‐way	 random	 trees	 classifier	 to	 interactively	 train	QuPath	 to	
distinguish	 tumour	 from	 non‐tumour	 cells.	 Secondly,	 to	 allow	 for	 variation	 in	
staining	intensity,	the	“H‐score”	method	of	scoring	was	applied.	[11]	This	requires	
manual	 calibration	 of	 negative,	 weak,	 moderate	 and	 strong	 immunostaining	
thresholds	 based	 upon	mean	 nuclear	 DAB	 optical	 densities,	 then	 the	 H‐score	 is	
calculated	from	the	extent	and	intensity	of	nuclear	staining,	whereby	H‐score	=	3	x	
%	of	strongly	staining	cells	+	2	x	%	of	moderately	staining	cells	+	1	x	%	of	weakly	
staining	cells,	giving	a	score	range	of	0	to	300.	In	contrast	to	manual	estimation	of	
H‐scores,	QuPath	provides	a	precise	cell‐by‐cell	total	in	this	calculation.	
	
Using	 these	 agreed	QuPath	approaches,	 but	without	 any	 further	 consultation	 on	
which	 cores	 to	 include/exclude	 from	 scoring	 or	 which	 parameters	 within	 the	
software	to	apply,	CD3	and	p53‐stained	TMAs	were	scored	independently	by	three	
reviewers,	 with	 differing	 backgrounds	 (pathology,	 biochemistry	 and	 computer	
science,	reviewers	1‐3	respectively)	and	differing	levels	of	experience	with	QuPath,	
the	 computer	 scientist	 (reviewer	 3)	 having	 written	 the	QuPath	 programme,	 the	
pathologist	 (reviewer	 1)	 having	 two	 years’	 experience	 in	 using	 QuPath	 and	 the	
biochemist	(reviewer	2)	having	received	only	two	weeks	training	in	QuPath	prior	
to	 this	 study.	 The	 data	 from	 reviewer	 3,	 using	 this	 scoring	 method,	 has	 been	
utilised	and	published	 in	one	prior	study.	 [3]	Manual	assessment	of	stained	TMA	
sections	was	conducted	by	one	reviewer	(reviewer	2)	for	CD3	only,	using	a	1	(low),	
2	 (moderate)	 and	 3	 (high)	 global	 assessment	 of	 numbers	 of	 positively	 staining	
cells.	
		
	
Statistical	Analysis	
	
QuPath	data	output	includes	total	numbers	of	cells	(staining	positive	or	negative)	
counted	within	each	core.	To	help	ensure	robustness	of	data,	any	cores	with	fewer	
than	 200	 cells	 detected	were	 removed	 from	 the	 statistical	 analysis.	 The	median	
score	from	the	remainder	of	the	triplicate	cores	for	each	case	was	then	derived	for	
each	 independent	 reviewer,	 and	 for	 each	 marker.	 For	 the	 purposes	 of	 intra‐
observer	comparison	in	this	study,	analysis	was	then	further	restricted	to	cases	for	
which	a	score	was	available	for	all	three	reviewers.	If	any	one	reviewer	excluded	
all	three	triplicate	cores	in	a	case,	all	reviewers’	scores	for	that	case	were	excluded.	
This	resulted	in	a	small	number	of	exclusions,	with	648	and	657	cases	remaining	
for	CD3	and	p53	analysis,	respectively.		
	
Median	 expression	 scores	 for	 each	 biomarker	 according	 to	 each	 independent	
reviewer	were	compared	between	colorectal	cancer	deaths	and	controls	using	the	
Wilcoxon‐rank	 sum	 test.	 	 For	 each	 reviewer,	 the	median	biomarker	 score	within	
controls	was	then	used	to	derive	dichotomous	categories	for	high	and	low	CD3	and	
p53	 expression.	 Kappa	 values	were	 then	 derived	 to	 compare	 the	 inter‐observer	
ability	 to	dichotomise	 individuals	 into	high	or	 low	expression	of	each	biomarker.	
Unadjusted	 Cox	 proportional	 hazards	models	 were	 then	 applied	 to	 evaluate	 the	
association	between	high	versus	low	biomarker	expression	and	colorectal‐specific	
survival,	 according	 to	 the	 scores	 created	 by	 each	 of	 the	 three	 independent	
reviewers.		Kaplan‐Meier	curves	were	created	to	visualise	survival	analysis	results.	
Finally,	 comparative	 analysis	 of	 manual	 and	 automated	 scoring	 of	 CD3	 by	 one	
reviewer	was	also	conducted.	QuPath	does	have	 internal	 capabilities	 for	deriving	
cut‐offs	 and	 producing	 survival	 curves	 for	 statistical	 analysis	 but,	 in	 this	 study,	
scores	were	exported	into	Stata	version	14.2	(StataCorp,	College	Station,	TX,	USA)	
for	 statistical	 analysis	by	 a	 further	member	of	 the	 study	 team	 independent	 from	
the	three	reviewers.	
	
Results	
	
 
Median	raw	scores	for	CD3	and	p53	were	highly	comparable	between	reviewers	1	and	3	
but	 differed	 significantly	 for	 reviewer	 2	 (Table	 1).	 However,	 this	 had	 little	 impact	 on	
subsequent	 analyses,	with	 data	 from	 all	 three	 reviewers	 yielding	 similar	 results.	 Lower	
CD3	scores	were	detected	in	cases	who	died	from	colorectal	cancer,	compared	to	control	
cases,	and	this	finding	was	significant	for	all	 three	reviewers	(p‐value	range	0.002‐0.02).		
Higher	median	p53	scores	were	generated	amongst	cases	who	died	from	colorectal	cancer	
compared	with	 controls,	 but	 this	 finding	was	 borderline	 or	 non‐significant	 for	 all	 three	
reviewers	(p‐value	range	0.04‐0.12).	
	
Similarly,	 all	 three	 reviewers	 produced	 dichotomised	 expression	 scores	 that	 resulted	 in	
very	 similar	 hazard	 ratios	 and	 95%	 confidence	 intervals	 for	 colorectal	 cancer‐specific	
survival	for	each	of	the	biomarkers	studied	(Table	2).	There	were	some	small	differences	
in	 the	magnitude	 of	 hazard	 ratios	 detected.	 For	 example,	 the	 reduced	 risk	 of	 colorectal	
cancer‐specific	death	varied	from	a	36%	reduced	risk	(HR	0.64)	to	a	28%	reduced	risk	(HR	
0.72)	 for	high	compared	with	 low	CD3	expression,	however	all	 three	reviewers	detected	
significant	 reductions	 in	 risk	 of	 death	 (p‐value	 range	 0.002‐0.02).	 The	 variation	 in	
magnitude	 of	 hazard	 ratios	 was	 smaller	 for	 p53	 expression,	 ranging	 from	 29‐33%	
increased	 risk	 of	 death	 for	 high	 compared	 with	 low	 p53	 H‐scores.	 These	 analyses	 all	
produced	 borderline	 significant	 associations	 (p‐value	 range	 0.04‐0.07).	 Kaplan‐Meier	
survival	curves,	based	on	data	from	each	reviewer,	demonstrated	highly	similar	patterns	
of	curve	separation	for	each	biomarker	(Figures	2	&	3).	
	
Despite	 variations	 in	 raw	 scores,	 the	 ability	 to	 dichomotise	 cases	 into	 high	 versus	 low	
expression	 of	 CD3	 and	 p53	 showed	 excellent	 agreement	 between	 all	 three	 reviewers	
(Kappa	 score	 range	 0.82‐0.93,	 Table	 3).	 Similar	 results	were	 found	when	 Kappa	 values	
were	 generated	 to	 compare	 scoring	 in	 only	 the	 colorectal	 cancer	 deaths,	 or	 only	 the	
control	group	(data	not	shown).		
	
Results	 from	 manual	 and	 QuPath	 methods	 of	 CD3	 scoring,	 conducted	 by	 the	 same	
reviewer,	 were	 highly	 comparable	 (Table	 4).	 The	 highest	 category	 of	 CD3	 staining	was	
significantly	associated	with	a	reduced	risk	of	colorectal	cancer‐specific	death	when	both	
manual	and	QuPath	scoring	methods	were	applied.	However,	QuPath	scoring	had	greater	
ability	to	distinguish	low	and	medium	CD3	scoring,	resulting	in	a	stronger	dose‐response	
association	 with	 colorectal	 cancer	 death	 than	 manual	 scoring	 (p‐value	 for	 trend	 0.003	
compared	with	0.06).	
	
Discussion	
	
	
Precision	medicine	requires	robust,	standardised	and	reproducible	assessment	of	predictive	
and	prognostic	biomarkers.	The	 lack	of	 agreement	on	 such	biomarker	 scoring	has	been	 a	
longstanding	issue	both	in	research	and	clinical	domains.	Even	amongst	those	progressing	
to	 commercial	 production	 and	 clinical	 use,	 many	 biomarkers	 have	 been	 poorly	 validated	
and	 there	 is	 uncertainty	 about	 the	 interpretation	 of	 immunohistochemical	 test	 results,	 in	
particular.	[12,	13]		
	
With	 increasing	 availability	 and	decreasing	 costs	 of	whole	 slide	 scanning	 facilities,	 digital	
images	of	stained	sections	are	readily	available	for	analysis	and	digital	image	analysis	lends	
itself	to	reproducibility.	There	is	a	need,	therefore,	for	digital	image	analysis	software	which	
is	 accessible,	 versatile,	 transparent,	 applicable	 to	 all	 common	 image	 file	 types	 and	 can	
handle	 large	 file	 sizes,	 to	meet	 the	 challenges	 of	 standardising	 biomarker	 assessments	 in	
research	and	clinical	settings.[14]	In	the	research	context,	the	development	of	open	source	
software	is	essential	to	provide	the	scientific	community	with	freely‐available	tools	that	can	
be	 utilised,	 interrogated	 and	 customised	 for	 both	 established	 and	 novel	 applications;	
however,	the	user‐friendliness	of	such	open	source	tools	can	often	be	lacking,	which	limits	
their	widespread	use.	 [15]	 	QuPath	 has	been	created	 to	 address	 this	need	 for	whole	 slide	
image	 analysis,	 and	 several	 recent	 studies	 have	 illustrated	 some	 of	 its	 potential	 for	 TMA	
biomarker	scoring.		[3,	5,	6]	In	this	study,	we	have	examined	some	important	issues	around	
the	use	and	 reproducibility	of	QuPath	 for	 biomarker	 scoring,	with	a	 view	 to	bringing	 this	
new	software	application	to	the	attention	of	a	broader	pathology	audience.	
	
Three	different	reviewers,	with	varying	experience	of	pathology	and	digital	image	analysis,	
ranging	from	minimal	to	many	years,	applied	the	same	agreed	QuPath	scoring	methodology	
to	a	 large	colon	cancer	cohort	presented	in	TMA	form,	 immunohistochemically	stained	for	
two	 well‐characterised	 and	 biologically	 diverse	 biomarkers,	 CD3	 and	 p53.	 We	 found	
considerable	variation	in	raw	QuPath	scores,	expressed	as	positive	cell	density	for	CD3	and	
H‐score	 for	 p53.	 	 This	 can	 be	 attributed	 to	 the	 different	ways	 in	which	 the	 software	was	
used;	nevertheless,	across	the	full	cohort	these	differences	had	little	impact	on	subsequent	
survival	 analysis	 for	 either	 biomarker,	 which	 demonstrated	 findings	 consistent	 with	
existent	 literature.	Excellent	 inter‐observer	 reproducibility	was	achieved	 in	dichotomising	
CD3	and	p53	scores.	Comparing	intra‐observer	manual	and	QuPath	scoring	for	CD3	revealed	
considerably	stronger	prognostic	stratification	for	QuPath	scores,	suggesting	greater	scoring	
accuracy	compared	to	the	manual	method.		
	
The	observed	variation	in	raw	scores	was	explored	further	by	review	of	annotated	QuPath	
images	for	each	of	the	three	study	participants.	This	variation	was	explained	by	(a)	selection	
of	 different	 cores	 for	 scoring	 within	 the	 triplicate	 cores	 available	 for	 each	 case	 or	 (b)	
selection	 of	 different	 analysis	 parameters	 (e.g.	 thresholds)	within	QuPath	 settings	 for	 cell	
detection	 (CD3	 and	 p53)	 and	 for	 staining	 intensity	 calibration	 (p53	 only).	 	 Accurate	
selection	of	appropriate	parameters	requires	experience	of	evaluating	pathology	images	and	
IHC	in	particular.	Selection	of	different	annotated	regions	for	cell	classification	during	p53	
scoring	 may	 have	 influenced	 the	 accuracy	 of	 the	 tumour/non‐tumour	 classification	 and	
contributed	 to	differential	 raw	scores.	As	a	result	of	 this	additional	cell	 classification	step,	
one	may	have	expected	greater	inter‐observer	variation	in	p53	scoring	than	in	CD3	scoring,	
but	 the	 converse	was	observed	 (Table	3).	 	 This	may	be	 explained	partly	by	 the	 relatively	
higher	sophistication	of	the	p53	analysis	methodology,	being	more	robust	and	less	subject	
to	 tissue	artefacts,	and	also	 less	heterogeneity	 in	p53	expression	being	present	within	 the	
triplicate	 cores.	 Scrutiny	 of	 outlier	 cases	 with	 discordant	 CD3	 scoring	 suggested	 that	
exclusion	of	different	cores	from	scoring	by	each	reviewer,	from	the	triplicate	set	available	
for	each	case,	contributed	to	this	discordance.	
	
The	 reviewer	with	 little	 experience	 of	 pathology	 images	 produced	 scores	which	 diverged	
considerably	 from	 those	 of	 the	 other	 two	 reviewers.	 However,	 this	 had	 little	 impact	 on	
stratification	 of	 scores	 for	 that	 reviewer,	 as	 any	 error	was	 consistently	 applied	 across	 all	
images,	 hence	 the	 lack	 of	 any	 significant	 detriment	 to	 comparative	 survival	 analyses.	
Nevertheless,	while	somewhat	reassuring	regarding	the	robustness	of	the	digital	analysis,	it	
would	be	remiss	to	underestimate	the	importance	of	specialist	knowledge	and	experience	in	
the	 application	 of	 digital	 biomarker	 scoring.	 	 For	 greatest	 scoring	 accuracy,	 it	 is	 highly	
recommended	 that	 input	 from	 a	 suitably	 trained	 pathologist	 is	 sought,	 particularly	 for	
critical	 points	 such	 as	 cell	 classification	 and	 selection	 of	 suitable	 thresholds,	 for	 example	
relating	 to	 tissue	 detection	 and	 in	 calibration	 of	 mild,	 moderate	 and	 strong	 staining	
intensity.	 This	 input	 may	 alternatively	 be	 provided	 by	 a	 laboratory	 scientist	 sufficiently	
experienced	in	viewing	IHC	slides.	Identifying	artefacted	cores	and	judging	whether	or	not	
sufficient	 artefact	 is	 present	 to	 exclude	 such	 cores	 from	 the	 study	 also	 benefits	 from	
pathology	 experience.	 Additionally,	 an	 understanding	 of	 the	 basic	 principles	 of	 image	
processing	and	analysis	is	beneficial	 in	discerning	how	the	software	may	be	used	to	attain	
the	 best	 results.	 Consequently,	we	would	 suggest	 that	 the	 preferred	 arrangement	 is	 for	 a	
pathologist	and	bioimage	analyst	to	work	together	in	collaboration	to	design	and	verify	the	
analysis	methodology	employed.	
	
These	 results	 indicate	 that	 image	 analysis	 is	 not	 a	 panacea	 in	 terms	 of	 standardising	
biomarker	 scoring,	 and	 results	may	differ	 even	when	 the	 same	 software	 is	 applied	 to	 the	
analysis	 of	 the	 same	 data.	 	 In	 this	 study	 all	 three	 reviewers	 employed	 an	 agreed	 general	
approach,	 but	 this	 nevertheless	 afforded	 room	 for	 interpretation.	 	 This	 should	 serve	 as	 a	
warning	 against	 standardising	 cut‐offs	 based	 on	 absolute	 values	 produced	 through	 image	
analysis,	such	as	the	density	of	CD3	positive	cells	or	H‐score	for	p53,	because	these	values	
depend	upon	how	the	software	is	used.	 	Consequently,	the	reporting	of	raw	QuPath	scores	
should	ideally	be	accompanied	by	an	indication	of	precise	methodology	applied,	in	addition	
to	chosen	thresholds,	especially	 if	 these	differ	 from	default	QuPath	settings.	This	would	be	
particularly	problematic	 for	researchers	wishing	 to	use	ROC‐defined	cut‐offs	 to	determine	
high	or	 low	expression	categories	of	 a	biomarker.	To	assist	with	 this,	 key	parameters	 are	
automatically	 logged	 by	 QuPath	 during	 analysis,	 and	 may	 be	 exported	 to	 create	 batch	
processing	scripts.	 	Nevertheless,	 it	must	be	kept	 in	mind	that	the	 final	results	will	clearly	
depend	not	only	on	the	analysis	methodology	and	parameters	used,	but	also	on	the	images	
themselves	–	and	hence	on	the	laboratory	protocols	(in	particular	tissue	section	thickness,	
IHC	 procedures)	 and	 scanner	 involved	 in	 generating	 the	 digital	 whole	 slide	 images.		
Consequently,	running	precisely	the	same	image	analysis	approach	(using	any	software)	on	
images	or	data	generated	 in	different	 laboratories	does	not	 guarantee	 true	 comparability,	
and	 careful	 quality	 control	 is	 required	 at	 all	 stages	 to	 ensure	 the	 results	 are	 valid	 and	
meaningful.	The	ability	within	QuPath	to	review	instantly	any	changes	to	the	image	mark‐up	
following	changes	to	the	analysis	method	is	an	invaluable	tool,	especially	for	pathologists	for	
whom	“seeing	 is	believing”	as	 far	as	 image	data	verification	 is	concerned.	Of	note,	QuPath	
analysis	 in	 this	 study	 has	 been	 performed	 on	 images	 generated	 from	 two	 different	
automated	 IHC	 platforms	 (Leica	 and	 Ventana)	 and	 proved	 itself	 capable	 of	 handling	 any	
associated	variation.	
	
Immunoexpression	 data	 for	 p53	 has	 been	 presented	 and	 analysed	 in	 this	 study	 in	 a	
continuous	scale,	consistent	with	the	approach	taken	in	previous	studies.	[10,	16,	17]	This	
suits	 the	 focus	 of	 this	 study,	 which	 is	 comparability	 of	 digital	 image	 analysis	 scoring	 by	
QuPath,	 amongst	 different	 reviewers.	 However,	 given	 recent	 developments	 in	 the	
understanding	 of	 p53	 biology,	 and	 the	 relationship	 between	 different	 p53	mutations	 and	
immunoexpression	patterns,	it	is	now	considered	more	appropriate	to	analyse	p53	staining	
by	comparing	normal	or	“wild	type”	staining	with	aberrant	extremes	of	staining	(“mutation	
type”).	 [18‐20]	The	 latter	 approach	 to	p53	 analysis	 has	 been	 applied	 to	 this	 colon	 cancer	
cohort	and	reported	separately,	 finding	 that	aberrant	extremes	of	p53	 immunoexpression	
(diffuse	intense	or	completely	absent)	was	associated	with	significantly	poorer	unadjusted	
disease‐specific	survival	when	compared	with	“wild‐type”	expression	(p=0.003).	[4]	
	
We	 have	 demonstrated	 the	 feasibility	 and	 inter‐observer	 reproducibility	 of	 CD3	 and	 p53	
immunoscoring	 using	QuPath	 in	 the	 TMA	 setting,	 even	with	 limited	 experience	 of	 digital	
pathology	 images	 and	 minimal	 QuPath	 training.	 This	 may	 be	 extrapolated	 to	 equivalent	
tissue	 samples	and	 to	other	markers	 showing	 the	 similar	patterns	of	 staining.	QuPath	has	
also	 been	 utilised	 in	 recently	 published	 studies	 to	 score	 biomarkers	 demonstrating	
cytoplasmic	 (cyclooxygenase‐2,	 3‐hydroxy‐3‐methylglutaryl	 coenzyme‐A	 reductase)	 and	
membranous	(HER2)	tumour	cell	staining.	 [4‐6]	However,	biomarkers	with	more	complex	
patterns	of	staining,	such	as	mismatch	repair	proteins	or	immune	checkpoint	inhibitors,	for	
example	PD‐L1,	are	much	more	challenging	for	digital	scoring,	as	multiple	cell	populations	
are	stained	(tumour	and	inflammatory)	and	distinction	between	tumour	and	inflammatory	
cell	staining	can	be	difficult	when	the	pattern	of	staining	is	patchy.		Recently,	convolutional	
neural	 networks	 have	 shown	 great	 promise	 for	 pathology	 image	 analysis,	 and	 currently	
represent	the	state‐of‐the‐art	whenever	such	a	rigorous	cell	classification	 is	required.	 [21]	
However,	 to	 date	 the	 application	 of	 such	 ‘deep	 learning’	 analysis	 has	mostly	 focussed	 on	
haematoxylin	and	eosin	staining.	[22,	23]			
	
In	 summary,	 we	 demonstrate	 the	 functionality,	 even	 amongst	 inexperienced	 users,	 and	
inter‐observer	 reproducibility,	 of	 QuPath	 biomarker	 scoring	 in	 the	 setting	 of	
immunohistochemically	 stained	 tumour	 TMAs.	 This	 represents	 just	 one	 facet	 of	 this	
powerful,	new,	open	source	digital	 image	analysis	software,	which	may	help	 to	alleviate	a	
critical	bottleneck	in	tissue	biomarker	discovery	research.	 	
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Table	1.	Median	biomarker	expression	scores	for	CD3	(positive	cells/mm2)	and	p53	(H‐score)	
for	three	independent	reviewers.		
	
Biomarker	and	
Reviewer	
Number	of	cases*	 Median	
expression	
score**	
Interquartile	
range	
	
p‐
value***	
CD3	 	 	 	 	
Reviewer	1	 Controls	n=440	 567	 303‐984	 	
	 CRC	deaths	n=208	 450	 235‐835	 0.02	
Reviewer	2	 Controls	n=440	 862	 468‐1437	 	
	 CRC	deaths	n=208	 670	 333‐1249	 0.001	
Reviewer	3	 Controls	n=440	 554	 308‐933	 	
	 CRC	deaths	n=208	 429	 231‐750	 0.002	
p53	 	 	 	 	
Reviewer	1	 Controls	n=447	 89	 27‐242	 	
	 CRC	deaths	n=210	 136	 35‐256	 0.09	
Reviewer	2	 Controls	n=447	 19	 3‐98	 	
	 CRC	deaths	n=210	 39		 3‐117	 0.12	
Reviewer	3	 Controls	n=447	 102	 38‐249	 	
	 CRC	deaths	n=210	 161	 44‐266	 0.04	
								*Only	cases	were	included	where	scores	were	available	from	all	three	reviewers.	
								**Positive	cells/mm2	of	tissue	for	CD3	and	H‐score	for	p53.	
***Comparing	differences	in	median	expression	scores	between	CRC	deaths	and	controls.		
								CRC,	colorectal	cancer.	
	
Table	2.	Unadjusted	Hazard	ratios	and	95%	confidence	intervals	comparing	survival	of	
patients	with	colon	cancer	according	to	CD3	and	p53	biomarker	expression,	as	scored	
by	three	independent	reviewers.		
	
Biomarker	
and	
Reviewer	
Expression	score	 Number	of	
controls/		
CRC	deaths	
Unadjusted	hazard	
ratio	and	95%	
confidence	intervals	
p‐value	for	
trend	
CD3	 	 	 	 	
Reviewer	1	 Low	(<567)	 220/123	 1.00	 	
	 High	(≥567)	 220/85	 0.72	(0.55‐0.96)	 0.02	
Reviewer	2	 Low	(<862)	 220/130	 1.00	 	
	 High	(≥862)	 220/78	 0.64	(0.49‐0.85)	 0.002	
Reviewer	3	 Low	(<554)	 220/127	 1.00	 	
	 High	(≥554)	 220/81	 0.68	(0.51‐0.90)	 0.006	
p53	 	 	 	 	
Reviewer	1	 Low	(<89)	 223/87	 1.00	 	
	 High	(≥89)	 224/123	 1.32	(1.00‐1.73)	 0.05	
Reviewer	2	 Low	(<19)	 224/88	 1.00	 	
	 High	(≥19)	 223/122	 1.29	(0.98‐1.70)	 0.07	
Reviewer	3	 Low	(<102)	 224/86	 1.00	 	
	 High	(≥102)	 223/124	 1.33	(1.01‐1.75)	 0.04	
CRC,	colorectal	cancer.	
	
	
	 	
Table	3.	Kappa	values	reflecting	inter‐observer	variation	in	scoring	dichomotous	
categories	of	median	immunohistochemical	biomarker	expression	for	CD3	and	
p53.		
	
	 Reviewer	 1	 2	 Inter‐observer	agreement	
	
CD3	
(High	v.	low)	
2	 0.82	 	 Excellent	
3	 0.85	 0.86	 	
p53	
(High	v.	low)	
2	 0.93	 	 Excellent	
3	 0.93	 0.91	 	
	
	
	
	
Table	4.	Unadjusted	Hazard	ratios	and	95%	confidence	intervals	comparing	manual	and	
QuPath	scoring	of	CD3	immunoexpression,	as	scored	by	one	reviewer.		
	
Scoring	
method	
Expression	score	 Number	of	
controls/			
CRC	deaths	
Unadjusted	hazard	
ratio	and	95%	
confidence	intervals	
p‐value	
for	trend	
Manual	 1	 154/81	 1.00	 	
	 2	 221/110	 0.92	(0.69‐1.23)	 	
	 3	 71/21	 0.60	(0.37‐0.97)	 0.06	
QuPath	 Low	(<971)	 153/98	 1.00	 	
	 Medium	(971‐<2775)	 222/92	 0.71	(0.53‐0.95)	 	
	 High	(≥2775)	 71/21	 0.54	(0.34‐0.87)	 0.003	
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Legends	
	
Figure	1.	Key	steps	in	QuPath	methods	for	scoring	CD3	(A)	and	p53	(B).	
Figure	2.	Kaplan	Meier	curves	for	CD3	expression	and	colorectal	cancer‐specific	
survival.	
Figure	3.	Kaplan	Meier	curves	for	p53	expression	and	colorectal	cancer‐specific	
survival.	
	
	
	
	
	
	
